Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.32 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414499 | 1.00 | MAPK1 (0.34) | MAPK1P2RX7SLC9A1SLC9A5SLC9A2 | |
| SCHEMBL31394467 | 0.83 | MAPK1 (0.35) | MAPK1P2RX7SLC9A1 | |
| SCHEMBL12533487 | 0.83 | MAPK1 (0.35) | MAPK1P2RX7SLC9A1 | |
| SCHEMBL31394265 | 0.82 | LPL (0.35) | MAPK1P2RX7 | |
| SCHEMBL16140289 | 0.82 | MAPK1 (0.34) | MAPK1P2RX7SLC9A1 | |
| SCHEMBL15132885 | 0.82 | MAPK1 (0.34) | MAPK1P2RX7 | |
| SCHEMBL30634635 | 0.78 | SLC9A1 (0.38) | MAPK1P2RX7SLC9A1SLC9A5SLC9A2 | |
| SCHEMBL30938593 | 0.76 | P2RX7 (0.35) | MAPK1P2RX7 | |
| SCHEMBL27405718 | 0.76 | P2RX7 (0.35) | MAPK1P2RX7 | |
| SCHEMBL30973552 | 0.75 | MAPK1 (0.30) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630417-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630420-A1 | INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-4615841-A1 | TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025045961-A1 | INHIBITORS OF THE NLRP3 INFLAMMASOME | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-118234730-A | Heterocyclic NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024121086-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121184-A1 | INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| CN-118119626-A | Fused bicyclic heteroaryl compounds useful as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024099992-A1 | TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099992-A1 | TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024017924-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023088856-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |